UnknownNot Applicable

Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .

90 participantsStarted 2021-07-01

Plain-language summary

The purpose of the study is to determine whether plasma levels of the soluble urokinase plasminogen activator(suPAR) can serve as a blood-based biomarker for diagnosis of Behçet's disease and its correlation with disease activity.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 * Patients diagnosed as Behçet's disease according to international study group criteria (ICBD ) for diagnosis of Behçet's Exclusion Criteria: * Age\< 18 years * Other autoimmune diseases. * Pregnancy. * Acute and chronic systemic infection history. * The presence of chronic diseases such as chronic renal failure, liver and cardiac failure. * Presence or history of cancer.

What they're measuring

evaluation of the level of suPAR in the study subjects.

Timeframe: baseline

Trial details

NCT IDNCT04105439

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-11-01

Contact for this trial

Mohamed Farghaly Ramadan, MD

01120782662 el.5abiry@gmail.com

View on ClinicalTrials.gov More Behçet Disease trials